Company Overview
Genmab A/S operates as a biotechnology firm based in Denmark that specializes in the development of antibody-based products and product candidates designed for the treatment of cancer and other diseases. The company functions within the healthcare sector, specifically under the biotechnology industry, which focuses on utilizing biological agents to treat complex medical conditions. At a significant scale, Genmab A/S maintains a market capitalization of $15.89B and employs 2973 individuals across its operations. The annual revenue of $3.72B indicates that the company has established a substantial commercial footprint, generating significant income through its marketed therapies like EPKINLY and TEPKINLY. These financial metrics suggest the company holds a prominent position in the oncology market, leveraging its R&D capabilities to commercialize assets for adult patients with relapsed or refractory diffuse large b-cell lymphoma and other indications.
Financial Health
The company reported a trailing twelve-month revenue of $3.72B, with net income of $963.00M and EBITDA of $1.29B. The gap between the total revenue and net income reveals a cost structure where operating expenses, taxes, and other deductions consume approximately $1.76B of gross revenue to arrive at the final profit. Genmab A/S generated free cash flow of $1.07B, which provides substantial financial flexibility for funding research initiatives, acquiring technologies, or managing working capital needs without relying on external financing. The gross margin stands at 93.6%, indicating a highly scalable business model typical of biotechnology where production costs are relatively low compared to the selling price of the products. The operating margin is 23.0%, reflecting the efficiency of core operations after covering all operating costs, while the profit margin reaches 25.9%, demonstrating strong profitability on every dollar of sales. The company holds $1.72B in cash against total debt of $5.43B, resulting in a debt-to-equity ratio of 92.80, which indicates a leveraged balance sheet where liabilities significantly exceed equity. Despite the leverage, the current ratio of 2.02 suggests that the company maintains strong short-term liquidity, as it holds more than twice the value of current assets relative to its current liabilities. Return on equity is 17.5% and return on assets is 8.1%, metrics that reveal management is effectively utilizing shareholder capital and total assets to generate returns, though the ROA is moderated by the high level of debt on the books.
Valuation Assessment
Genmab A/S trades with a trailing P/E ratio of 16.71 and a forward P/E of 14.40. The difference between these two ratios implies that the market expects earnings growth in the future, as the forward multiple is lower than the historical multiple, suggesting the stock is priced to expand earnings per share. The price-to-book ratio is 0.27, which indicates that the market values the company at a significant discount to its book value, a common occurrence for biotechnology firms with high intangible assets and research pipelines not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 4.27 and an EV/EBITDA of 4.11, which suggest that investors are willing to pay a premium for revenue growth potential and earnings quality despite the high debt load. The 52-week high is $35.43 and the 52-week low is $17.23, placing the current implied trading context within a wide historical range that reflects market volatility and shifting sentiment regarding the company's pipeline progress. The beta value is 0.75, which means the stock is less volatile than the broader market, exhibiting lower price swings during periods of general equity market turbulence.
Growth & Income
Revenue growth year-over-year is 3.0%, while earnings growth year-over-year is -94.4%. The fact that earnings are shrinking significantly faster than revenue implies that the company may be facing increased costs, one-time charges, or a shift in the composition of revenue from high-margin products to lower-margin segments that is impacting the bottom line more aggressively than the top line. Genmab A/S does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all of its net income into expanding its business rather than distributing cash to shareholders. This strategy prioritizes capital allocation toward research and development to sustain long-term growth in the competitive oncology landscape. The overall growth and income profile is characterized by moderate top-line expansion offset by a sharp contraction in profitability, with no income yield for investors seeking current cash returns.